It is also recommended for the treatment of lymphocytic lymphoma patients who have received at least two prior systemic therapies or patients with relapsed follicular B-cell NHL.389 Copanlisib, approved in September 2017, is a pan-PI3K inhibitor with IC50 values of 0.5, 3.7, 6.4, and 0.7 nM against class I PI3K-α, β, γ, and δ isoforms, respectively.390 It is used clinically for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. The gene discussed is PIK3CB; the disease is follicular lymphoma.